“…Sensitivities of Xpert ® MTB/RIF and its ultra version reported in fresh non-FFPE clinical samples, so far, are always higher than 60% ( Tortoli et al, 2012 ; Sauzullo et al, 2016 ; Lee et al, 2017 ; Bahr et al, 2018 ; Dorman et al, 2018 ; Sarfaraz et al, 2018 ; Sulis et al, 2018 ; Aydemir et al, 2019 ; Kohli et al, 2021 ) and can reach more than 90% only in some body districts ( Mazzola et al, 2016 ). The few data available regarding the Xpert assay performances in FFPE samples are based on a few clinical biopsies and reported a wide range of sensitivities, which were not even concordant (from 97.6% in the case of the Ultra version to 53.2% in the case of the first MTB/RIF assay) ( Seo et al, 2014 ; Du et al, 2019 ; Njau et al, 2019 ; Budvytiene and Banaei, 2020 ; Huang et al, 2020 ). Some of these reports also suggest different sensitivities against the sites of biopsies (i.e., lymph node vs. non-lymph nodes sites) ( Polepole et al, 2017 ).…”